Stock analysts expect Xencor, Inc. (NASDAQ:XNCR – Get a rating) to post earnings of ($0.78) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts made Xencor earnings estimates, with the lowest EPS estimate of $1.07 and the highest estimate of $0.60. Xencor posted earnings of ($0.04) per share in the same quarter last year, indicating a negative growth rate of 1,850% year over year. The company is expected to release its next earnings report on Monday, January 1.
According to Zacks, analysts expect Xencor to report full year earnings of ($2.96) per share for the current fiscal year, with EPS estimates ranging from ($4.41) to ($2. $03). For next year, analysts expect the company to post earnings of ($3.24) per share, with EPS estimates ranging from ($4.32) to ($2.13). Zacks earnings per share averages are an average based on a survey of research companies that track Xencor.
Xencor (NASDAQ:XNCR – Get a rating) last announced its results on Wednesday, February 23. The biopharmaceutical company reported earnings per share (EPS) of $1.21 for the quarter, beating the consensus estimate of $0.47 by $0.74. The company posted revenue of $154.02 million for the quarter, compared to $76.29 million expected by analysts. Xencor had a return on equity of 12.80% and a net margin of 30.04%. The company’s revenue for the quarter increased 268.0% year over year. In the same quarter last year, the company achieved EPS of ($0.24).
A number of analysts have weighed in on the company recently. TheStreet upgraded Xencor from a “d+” rating to a “c” rating in a Wednesday, February 23 research report. Zacks Investment Research upgraded Xencor from a “buy” rating to a “hold” rating in a Thursday, February 17 research report. HC Wainwright lowered its price target on Xencor from $61.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 24. Cantor Fitzgerald reaffirmed an “overweight” rating on Xencor shares in a Friday, April 1 research report. To finish, StockNews.com began covering Xencor in a research report on Thursday, March 31. They set a “holding” rating for the company. Two investment analysts gave the stock a hold rating and nine gave the stock a buy rating. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $53.88.
Shares of Xencor stock traded down $1.00 during Monday’s trading, hitting $25.69. The company’s shares had a trading volume of 295,113 shares, compared to an average trading volume of 336,114. The company has a market capitalization of $1.50 billion, a price-earnings ratio of 19.03 and a beta of 0.81. Xencor has a 1-year low of $25.45 and a 1-year high of $45.21. The company has a 50-day simple moving average of $29.57 and a two-hundred-day simple moving average of $34.55.
Separately, Chief Financial Officer John J. Kuch sold 971 Xencor shares in a trade dated Thursday, March 3. The stock was sold at an average price of $29.86, for a total value of $28,994.06. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, CEO Bassil I. Dahiyat sold 2,929 Xencor shares in a trade dated Thursday, March 3. The stock was sold at an average price of $29.90, for a total value of $87,577.10. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 9,524 shares of the company valued at $279,886. 3.68% of the shares are held by insiders of the company.
A number of hedge funds have been buying and selling shares of XNCR recently. First Trust Advisors LP increased its stake in Xencor by 185.4% in the 1st quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company worth $2,167,000 after buying an additional 45,331 shares in the last quarter. Royal Bank of Canada increased its holdings of Xencor shares by 145.4% during the second quarter. Royal Bank of Canada now owns 5,417 shares of the biopharmaceutical company worth $187,000 after buying 3,210 more shares in the last quarter. New Jersey State Joint Pension Fund D increased its holdings of Xencor stock by 39.0% during the third quarter. New Jersey State Joint Pension Fund D now owns 85,732 shares of the biopharmaceutical company worth $2,800,000 after buying 24,052 more shares in the last quarter. Maryland State Retirement & Pension System acquired a new stock position in Xencor during Q3 worth approximately $755,000. Finally, SG Americas Securities LLC increased its stake in Xencor shares by 753.9% in the 3rd quarter. SG Americas Securities LLC now owns 30,194 shares of the biopharmaceutical company worth $986,000 after buying 26,658 additional shares in the last quarter. Institutional investors hold 98.78% of the company’s shares.
Xencor Company Profile (Get a rating)
Xencor, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of monoclonal antibodies and therapeutic cytokines to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab which targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Xencor and related companies with MarketBeat.com’s FREE daily newsletter.